Sermorelin is a gentler, lower-cost growth hormone peptide. Like tesamorelin, it prompts your own pituitary to release GH and raise IGF-1, and it is dosed daily and titrated to your labs. This page covers what it is, where the evidence stands, our view on using it, and how it is dosed and monitored.
Reviewed by Dr. David Oliak, board-certified surgeon
Updated August 2026
Sermorelin is an analog of growth-hormone-releasing hormone (GHRH) — specifically the shortest fully active fragment of that natural hormone. It has a long clinical history: it was FDA-approved in the 1990s (as Geref) for growth hormone deficiency and pituitary testing, and that product was later discontinued for commercial reasons, not safety.
It signals the pituitary to release your own growth hormone in its natural, pulsatile pattern, and that GH prompts the liver to produce IGF-1, which carries most of the effects.
Sermorelin clears the body quickly, in roughly ten to twenty minutes, so it delivers a brief, gentle stimulus. That produces a more modest IGF-1 rise than the stronger, longer-acting tesamorelin. For many people that gentler rise is exactly what is appropriate.
As with any growth hormone peptide, the reason to consider it is that GH and IGF-1 decline with age. The aim is to restore them toward an age-appropriate level — here with a gentler stimulus — not above it.
Where the evidence stands for sermorelin.
Sermorelin's mechanism is well established and it has a real regulatory history, though its formal data is in growth-hormone-deficiency testing rather than general wellness, where use is off-label.
Our own experience with sermorelin is more limited than with tesamorelin: in most cases we favor tesamorelin for a more reliable IGF-1 response. We reach for sermorelin when a gentler rise or lower cost is the priority.
Our verdict: sermorelin and tesamorelin do the same thing through IGF-1; the difference is strength and cost. We reach for sermorelin when a gentler rise is appropriate or cost matters, and it has a reassuring regulatory history behind it.
In our own practice we use it less than tesamorelin, which more reliably reaches an age-appropriate IGF-1 target. So if a patient needs a larger response than sermorelin comfortably provides, that is usually the signal to consider tesamorelin instead.
As with tesamorelin, we use it as one targeted tool within a plan built on the evaluation: dosed daily rather than in cycles, because GHRH analogs keep growth hormone under the body's own feedback. And it is titrated to IGF-1 rather than to a fixed dose.
— Dr. David Oliak, board-certified physician and surgeon
Sermorelin is dosed once daily at bedtime, on an empty stomach, to align with the body's natural nighttime GH release. We dose it continuously, without cycling, and titrate to an age-appropriate IGF-1.
We use sermorelin at 0.5 mg, or half that to start or maintain; we do not use higher doses. Sermorelin is prescribed through a monthly membership that includes medication, shipping, and follow-up visits; labs are billed separately at Quest (no lab markup). For current pricing, see the peptide pricing page.
Sermorelin is prescribed only after a comprehensive evaluation, because dosing it depends on lab data. Before starting, we run a full panel including IGF-1 and metabolic markers.
We recheck IGF-1 at roughly eight to twelve weeks and then quarterly, titrating to an upper age-appropriate range rather than a supraphysiologic one, and we monitor glucose since growth-hormone secretagogues can affect blood sugar.
With any injected peptide, the source is a safety issue, not a detail — and with a lab-titrated therapy, so is the monitoring. We prescribe compounded, human-use sermorelin through a licensed pharmacy, not research-only material sold online, which is labeled not for human use and produced without a regulatory framework to confirm its contents.
Reported side effects are generally mild and can include injection-site reactions and, less often, fluid retention, which we limit by titrating to a physiologic IGF-1.
Because IGF-1 is a growth signal, sermorelin is not appropriate for people with active or recent cancer, and is used cautiously in uncontrolled diabetes and proliferative diabetic retinopathy.
It is prescribed off-label for wellness, under supervision, with informed consent. [Why "research use only" peptides are a problem →]
Let's begin
Sermorelin is prescribed after a comprehensive evaluation, including IGF-1, and is dosed to your labs over time. The evaluation is what lets us fit it to you as one targeted part of a plan — start there to see whether it fits your goals. To speak with us first, call 714-671-2005.
Growth hormone peptides, explained
Tesamorelin vs. Sermorelin — the comparison
Tesamorelin — the stronger GHRH analog
Why "research use only" peptides are a problem
It is used to raise your own growth hormone and IGF-1 for wellness goals such as recovery, sleep, and body composition. It is prescribed off-label for these uses.
We dose it daily at bedtime, at 0.5 mg, or 0.25 mg to start or maintain. We do not use higher doses; if a larger response is needed, that points to tesamorelin. The dose is set by your provider to your IGF-1.
Both work the same way, through IGF-1. Sermorelin is gentler and lower-cost; tesamorelin is stronger and produces a larger IGF-1 rise, and it is the one we use more often. We choose based on your goals and baseline labs. See the comparison page for detail.
It was previously FDA-approved (as Geref) and later discontinued for commercial reasons; it is now compounded. It is not currently an FDA-approved product, and wellness use is off-label.
Through a monthly membership (one vial per month) that includes medication, shipping, and visits; labs are billed separately at Quest. Current pricing is on our peptide pricing page. A comprehensive evaluation is required first.
